Stockscreener 앱 받기
0.33%
시간 외 거래:
전일 마감가:
$24.25
열려 있는:
$24.345
하루 거래량:
26.81M
Relative Volume:
0.68
시가총액:
$137.76B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
18.53
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
-0.62%
1개월 성능:
-5.59%
6개월 성능:
-5.14%
1년 성능:
-6.25%
1일 변동 폭
$24.09
$24.41
1주일 범위
$23.62
$24.41
52주 변동 폭
$23.11
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.17 | 138.21B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? - AOL.com
Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA - Moomoo
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Benzinga
FDA Approves Expanded Use of Pfizer's Padcev (PFE) with Merck's Keytruda - GuruFocus
Pfizer Poised for Mixed Second Quarter, RBC Says - marketscreener.com
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Singapore
Nathan Berman communicating with investors over Pfizer project - The Real Deal
Pfizer wins FDA label expansion for Padcev plus Merck’s Keytruda in bladder cancer - Seeking Alpha
BofA Securities Adjusts Pfizer Price Target to $26 From $27 - marketscreener.com
Pfizer Vaccine Dispute Hits Polish, Romania Air Traffic Agencies - ThePrint
McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait - AOL.com
PFIZER INC : RBC reiterates its Neutral rating - marketscreener.com
Pfizer Seen Reporting Q2 Revenue In Line With Consensus, EPS Below Estimates, RBC Says - marketscreener.com
Polish air traffic control faces funding freeze over COVID vaccine ruling - marketscreener.com
Jim Cramer on Pfizer: “I Can’t Come Up With Where the Growth Is” - Yahoo Finance
This Week’s Leadership Moves: Pfizer, Commonwealth Bank, and GE HealthCare - CDO Magazine
Stability concerns linger at former Pfizer building - PIX11
Stability concerns linger for former Pfizer building - PIX11
Pfizer's Depo-Provera Settlement: What Women With Meningioma Need to Know About the June 2026 Agreement - JD Supra
Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look - simplywall.st
Pfizer Trades at Just 8.5x Earnings While Peers Fetch 16x. Is the Discount Justified? - TIKR.com
Pfizer building inspector, subcontractor’s violations face scrutiny as probes proceed - The Real Deal
Pfizer Fails to Revive $108 Million Cancer-Drug Patent Verdict - Bloomberg Law News
NYC workers continue stabilizing 29 floors of former Pfizer HQ in Midtown. Here's the latest on the investigation. - CBS News
Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative? - Yahoo Finance
AstraZeneca wins appeal in Pfizer patent dispute over Tagrisso By Investing.com - Investing.com Canada
Efforts continue to shore up former Pfizer headquarters after concerns of collapse - CBS News
Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study - TipRanks
BridgeBio hits 52-week high on late-stage trial setback for Astra/ Ionis (update) - Seeking Alpha
‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend - Yahoo Finance
BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board - Yahoo Finance Singapore
Pfizer Inc. outlines pipeline priorities as a major U.S. drugmaker - Ad-hoc-news.de
PFE Stock Quote Price and Forecast - CNN
MetroLoft says it has ‘identified the issue’ with the old Pfizer building - PIX11
NCLA to Fifth Circuit: Revive Suit Against Gov’t-Led Censorship of Covid Vaccine-Injured Americans - GlobeNewswire Inc.
Mamdani believes Pfizer building issue was a ‘breakdown’ - pix11.com
Pfizer (PFE) On IBRANCE Approval And Dividend Move Has Valuation Back In Focus - simplywall.st
Pfizer Building Developer Says Buckled Columns Were 'Freak Accident' Caused by Weight of New Addition - Realtor.com
Enterprise value to EBIT forward of Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs – BCBA:PFE.B - TradingView
Engineering Failure Likely Behind Pfizer Project Scare - The Real Deal
Former Pfizer headquarters now "safe and stable" after steel columns buckled - CBS News
Stabilization efforts continue at old Pfizer building - PIX11
Did the old NYC Pfizer building collapse? Not quite - PIX11
After collapse scare, Pfizer building stabilization efforts continue - The Real Deal
Is Pfizer (PFE) Undervalued After IBRANCE Won A New FDA Approval? - Yahoo Finance
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Then vs. Now: Molecular Design - Pfizer
JPMorgan Adjusts Price Target on Pfizer to $28 From $30 - marketscreener.com
How Pfizer’s (PFE) Dividend Record Separates Tax Treatment From Business Momentum - Yahoo Finance
Pfizer Prevnar 20 by Pfizer Inc.adult pneumonia protection pushes vaccine portfolio - AD HOC NEWS
Manhattan Building Remains Unstable; Officials Warn of Collapse - TODAY.com
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.72%
1.23%
자본화:
|
볼륨(24시간):